TEVA NYSE Week ended 07 Aug 2026

Weekly Investor Report

Teva Pharma Industries Ltd ADR · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 35.36 USD
1.0% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 7.8% above the Trend Line and sits at 90.6% of its 52-week range. The latest completed week returned 1.0%, after a 7.3% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers. Options positioning is bullish with 53/100 conviction, while the latest news-sentiment score is 60/100. Near-term considerations: price is close to its 52-week high; volume confirmation is below normal.

Setup score 55 out of 100
Latest Close 35.36 USD 7 Aug 2026
1W Return 1.0% latest completed week
4W Return 7.3% short-term follow-through
12W Return 3.1% quarterly tape
Trend Breadth 96.2% 50 of 52 weeks active
Volume Ratio 0.9x vs 13-week average
What is working
  • The trend backdrop is active with a 2-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Next-week expectancy is positive at 55.87% based on similar historical setup states.
What could go wrong
  • Activity pressure is negative, which weakens the current setup.
  • 3 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 1.0% Latest completed week; four-week move 7.3%. Indicator stack 60/0 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 55.87% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Bullish 53/100 conviction; expected move 4.1%. News sentiment 60/100 39 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 7.8% above the Trend Line and sits at 90.6% of its 52-week range. The latest completed week returned 1.0%, after a 7.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.7212-week average 0.69

12-week confirmation

Trend active11/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.72Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers33 reversal markers

No recent accumulation markers. 3 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 7.3% over four weeks, 3.1% over 12 weeks, and 116.0% over one year. The current trend has remained active for 2 consecutive weeks.

Performance by holding period

1W1.0%
4W7.3%
12W3.1%
26W1.9%
52W116.0%
Active trend streak2 weeks
Active weeks in one year50
Trend breadth96.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.63Latest activity-pressure read.
Pressure change-479.0%Four-week change in activity pressure.
Leadership10.21Latest relative-leadership reading.
RS change14.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 30 Jun 2026 Field coverage 91% Model confidence 91%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength53/100Blend of value, momentum, and quality. Underlying universe rank 48; rank 1 is best.
Value12/100Relative valuation strength. Underlying universe rank 89; rank 1 is best.
Quality81/100Profitability and accounting quality. Underlying universe rank 20; rank 1 is best.
Momentum96/100Medium-term price momentum. Underlying universe rank 5; rank 1 is best.
Growth30/100Revenue and earnings growth. Underlying universe rank 71; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework38/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
58.4x
Price divided by trailing earnings.
Price / sales
2.4x
Market value relative to trailing revenue.
EV / EBITDA
18.1x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
4.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
52.5%
Gross profit retained from each unit of revenue.
Operating margin
11.6%
Operating profit retained from revenue.
Free-cash-flow margin
14.1%
Free cash flow generated from revenue.
Return on invested capital
9.4%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
4.1%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
29.5%
Latest one-year free-cash-flow growth.
Piotroski F-score
8/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
4.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

TEVA shows bullish options pressure with a 53/100 conviction score, put-call volume ratio of 0.09, expected move of 4.1%, and Sharemaestro trend signal active.

Conviction53/100
Expected move4.1%
Put/call volume0.09
Pressure91
Speculation41
Volatility51
Trend agreement4
Open options detail
Insider activity12 / 8

12 acquisitions and 8 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment60/100

Weighted news tone is positive across 39 relevant articles.

19 positive · 17 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move4.1%Nearest-chain priced movement where available.
52-week drawdown-5.3%Distance below the 52-week high.
13-week volatility5.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+14.1%Week of 1 May.
Worst week-9.1%Week of 19 Jun.
Latest week+1.0%Week of 7 Aug.

Shape of recent returns

Strong gains6
Modest gains8
Flat weeks0
Modest losses6
Sharp losses6
Recent vol5.6%13-week weekly-return volatility.
Base vol5.7%52-week weekly-return volatility.
Up/down split32/20Count of positive and negative weeks in the 52-week window.
Average skew5.0% / -3.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape53/100

Trend, activity pressure, participation, and risk combine to a 53/100 tape read.

 Indicator analysis64/100

Latest 12-week confirmation: trend 11/12, activity pressure 4/12, relative leadership 12/12.

Activity pressure 0.72; 3 reversal markers Next-Week ExpectancyPositive 55.87%

Next-week expectancy is positive with a 55.87% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors59/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 67 SVQF38/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 627.0 of 1018 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options49/100

TEVA shows bullish options pressure with a 53/100 conviction score, put-call volume ratio of 0.09, expected move of 4.1%, and Sharemaestro trend signal active.

Bullish · Call-side pressure · Expected move 4.1% Sentiment60/100

Weighted news tone is positive across 39 relevant articles.

Teva (TEVA) Is Up 6.0% After Moody’s Upgrade To Investment Grade And Higher 2026 Guidance Insiders12 / 8

12 acquisitions and 8 disposals in the latest 180-day insider tape.

 Earnings50/100

No stored earnings event is currently attached to this ticker.

 Research flow1 items

1 recent research articles and 0 Market Watch posts are available.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 202635.36 USD1.0%32.80 USD19.59 USD-0.6310.2124.5MOn
31 Jul 202635.01 USD13.6%32.69 USD19.43 USD-0.5713.9941.6MOn
24 Jul 202630.81 USD-3.8%32.56 USD19.27 USD-0.602.4722.1MOff
17 Jul 202632.03 USD-2.8%32.59 USD19.13 USD-0.286.6821.3MOn
10 Jul 202632.95 USD-4.9%32.54 USD18.98 USD-0.118.9428.1MOn
3 Jul 202634.64 USD4.3%32.43 USD18.82 USD0.0517.0517.7MOn
26 Jun 202633.21 USD5.5%32.23 USD18.65 USD0.0815.7131.1MOn
19 Jun 202631.48 USD-9.1%32.01 USD18.48 USD0.118.0328.3MOn
12 Jun 202634.63 USD1.3%31.77 USD18.33 USD0.0920.7329.1MOn
5 Jun 202634.19 USD-3.2%31.46 USD18.15 USD-0.0420.9533.3MOn
29 May 202635.32 USD3.7%31.12 USD17.98 USD-0.0522.8329.2MOn
22 May 202634.07 USD-0.6%30.63 USD17.80 USD-0.0321.3121.6MOn
15 May 202634.29 USD-4.0%30.13 USD17.63 USD-0.2024.1827.2MOn
8 May 202635.73 USD2.2%29.63 USD17.46 USD-0.3430.8539.7MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context